An ACE inhibitor or beta-blocker can significantly reduce cardiotoxicity in women with HER2-positive breast cancer being treated with doxyrubicin and trastuzumab (Herceptin). The findings, presented at the American College of Cardiology’s 67th Annual Scientific Session in Orlando, showed lower cardiac event rates with ACE inhibitors (37%) and beta-blockers (31%) compared to placebo (47%). However the ...
ACC: Two drugs to offset the CV risk in HER2-positive breast cancer
By Mardi Chapman
13 Mar 2018